By Counterforce Health Team in Opdivo (nivolumab) —

How to Get Opdivo (Nivolumab) Covered by Cigna in New Jersey: Complete Prior Authorization and Appeals Guide

Quick Answer: Getting Opdivo Covered by Cigna in New Jersey

Opdivo (nivolumab) requires prior authorization from Cigna in New Jersey. Your oncologist must submit an electronic PA through CoverMyMeds or Cigna's provider portal with complete clinical documentation including diagnosis, staging, prior treatments, and biomarker results where required. If denied, you have 180 days to file an internal appeal, followed by New Jersey's Independent Health Care Appeals Program (IHCAP) for external review. Start today: Have your doctor gather your pathology report, treatment history, and submit the PA electronically—approvals typically take 3-5 business days with complete documentation.

Table of Contents

Cigna Plan Types and Opdivo Coverage

Understanding your specific Cigna plan type is crucial for Opdivo coverage in New Jersey. Each plan structure affects your access to specialists, prior authorization requirements, and cost-sharing responsibilities.

Commercial Plans (HMO vs PPO)

  • Cigna HMO plans require you to choose a primary care physician and typically need referrals to see specialists like oncologists. All care must be in-network except for emergencies.
  • Cigna PPO plans offer more flexibility, allowing you to see specialists without referrals and providing some coverage for out-of-network providers (though at higher cost).

Medicare Advantage Plans

New Jersey offers several Cigna Medicare Advantage options for 2025:

  • Cigna Preferred Medicare (HMO): $0 premium with drug coverage
  • Cigna True Choice (PPO): $0 premium, $500 deductible with drug coverage
  • Cigna Courage Medicare (HMO): Does not include prescription drug coverage
Important: Verify your specific plan includes prescription drug coverage before assuming Opdivo will be covered. Some HMO plans exclude drug benefits entirely.

Formulary Status and Cost Sharing

Opdivo is classified as a specialty medication on Cigna formularies, typically placed in Tier 4 or Tier 5 (the highest cost-sharing tiers). This placement means significant out-of-pocket costs unless you qualify for assistance programs.

Coverage at a Glance

Requirement Details Where to Verify
Prior Authorization Required for all indications Cigna PA Forms
Formulary Tier Specialty (Tier 4/5) Current year Cigna formulary
Step Therapy May apply depending on cancer type PA submission will indicate
Quantity Limits Dosing frequency restrictions possible Plan-specific formulary
Specialty Pharmacy Accredo required for most plans Cigna member services

Prior Authorization Requirements

Cigna requires electronic prior authorization submission for Opdivo through CoverMyMeds or compatible EHR systems. Manual fax submissions are being phased out.

Required Clinical Documentation

Your oncologist must provide:

  • Diagnosis with ICD-10 codes and cancer staging
  • Pathology reports confirming tumor type and characteristics
  • Prior treatment history including therapies tried, duration, and outcomes
  • Biomarker testing results (PD-L1 expression, MSI status, etc.) where clinically indicated
  • Treatment plan with dosing regimen and monitoring schedule

Biomarker Requirements by Cancer Type

  • Melanoma: Generally no specific biomarker requirements
  • NSCLC: May require EGFR/ALK testing results for certain treatment settings
  • Renal cell carcinoma: Typically requires clear cell histology confirmation
  • Head and neck cancers: May require HPV status documentation
Clinician Tip: Submit comprehensive documentation upfront. Incomplete submissions delay approval and may trigger automatic denials that require appeals.

Specialty Pharmacy Setup with Accredo

Most Cigna plans require Opdivo to be dispensed through Accredo, Cigna's preferred specialty pharmacy. This process begins automatically once your prior authorization is approved.

Enrollment Process

  1. Physician referral: Your doctor submits the Accredo referral form alongside the PA
  2. Patient contact: Accredo calls within 24-48 hours to verify insurance and coordinate delivery
  3. Account setup: Create your online account at Accredo.com using your prescription number
  4. Delivery coordination: Home delivery with temperature-controlled shipping for infusion centers

What Accredo Provides

  • Clinical pharmacist consultations
  • Injection training and education materials
  • Refill reminders and adherence monitoring
  • Insurance and copay assistance coordination
  • 24/7 clinical support hotline

Common Denial Reasons and Solutions

Understanding why Cigna denies Opdivo requests helps you prepare stronger submissions and appeals.

Denial Reason How to Address
Insufficient medical necessity Include comprehensive clinical notes, staging, and treatment rationale
Missing biomarker testing Submit required PD-L1, MSI, or other relevant biomarker results
Step therapy not met Document prior therapies tried, durations, and reasons for discontinuation
Off-label use Provide peer-reviewed literature and guideline support for indication
Incomplete clinical information Ensure pathology, staging, and performance status are clearly documented

Strengthening Your Submission

When preparing your prior authorization, Counterforce Health helps clinicians and patients turn insurance denials into targeted, evidence-backed appeals by analyzing denial letters and crafting point-by-point rebuttals aligned with payer policies. Their platform identifies specific denial reasons and pulls the right clinical evidence to support approval.

Internal Appeals Process

If Cigna denies your Opdivo prior authorization, you have 180 days from the denial date to file an internal appeal.

First-Level Internal Appeal

  • Timeline: Submit within 180 days of denial
  • Review period: 30-60 days for standard appeals, 72 hours for expedited
  • Requirements: Include denial letter, additional clinical documentation, and physician appeal letter
  • Submission: Use Cigna's appeals portal or mail to address on denial letter

Second-Level Internal Appeal

  • Timeline: 60 days from first-level denial
  • Process: Independent medical review by Cigna physicians
  • Peer-to-peer option: Request direct physician-to-physician discussion
Expedited Appeals: If delay could seriously jeopardize your health, request expedited review. Cigna must respond within 72 hours for urgent cases.

New Jersey External Review Rights

New Jersey offers robust external review rights through the Independent Health Care Appeals Program (IHCAP), now administered by Maximus Federal Services.

When You Can Appeal Externally

  • Completed both levels of Cigna's internal appeals
  • Denial based on medical necessity or similar coverage criteria
  • Have a New Jersey-regulated insurance plan
  • Submit within 4 months (180 days) of final internal denial

IHCAP Process

  1. Submit request directly to Maximus (contact info provided after internal appeals)
  2. Preliminary review within 5 business days to confirm eligibility
  3. Independent physician review by specialists in your cancer type
  4. Decision typically within 45 days (expedited available for urgent cases)
  5. Binding result: If overturned, Cigna must cover Opdivo

New Jersey Consumer Resources

About half of external appeals nationwide favor consumers, making New Jersey's IHCAP a valuable option when Cigna's internal process doesn't resolve your case.

Cost Assistance Programs

Opdivo's high cost—approximately $7,943 per 240mg vial—makes financial assistance crucial for most patients.

Manufacturer Support

  • Bristol Myers Squibb Access Support: Copay cards for eligible commercially insured patients
  • Patient Assistance Program: Free medication for qualifying uninsured/underinsured patients
  • Information: Contact BMS Access Support at 1-800-721-8909

Foundation Grants

  • HealthWell Foundation: Grants for cancer patients with insurance
  • Patient Access Network Foundation: Copay assistance for specialty medications
  • CancerCare: Financial assistance and case management

Accredo Assistance Coordination

Accredo's financial advocates help identify and apply for assistance programs, coordinating between manufacturer support, foundations, and your insurance benefits.

For comprehensive assistance with navigating these programs and strengthening your coverage appeals, Counterforce Health provides specialized support for patients and clinicians dealing with complex prior authorization challenges.

FAQ

How long does Cigna prior authorization take for Opdivo in New Jersey? Electronic submissions through CoverMyMeds typically receive responses within 3-5 business days with complete documentation. Incomplete submissions may take 2-3 weeks.

What if Opdivo isn't on my Cigna formulary? You can request a formulary exception by submitting clinical documentation showing medical necessity and lack of suitable alternatives on formulary.

Can I get expedited review if my cancer is progressing? Yes. Both Cigna's internal appeals and New Jersey's IHCAP offer expedited review for urgent medical situations where delay could cause serious harm.

Do I need my primary care doctor's referral for Opdivo? HMO plans typically require referrals to oncologists, but the oncologist handles the Opdivo prior authorization. PPO plans don't require referrals.

What happens if I move from New Jersey during treatment? Your Cigna coverage continues, but external review rights will follow your new state's regulations. Notify Cigna and Accredo of address changes immediately.

Can my doctor request a peer-to-peer review? Yes. Physicians can request direct discussion with Cigna's medical directors, often resolving denials faster than formal appeals.

Sources & Further Reading

Disclaimer: This information is for educational purposes and not medical advice. Coverage policies vary by plan and change regularly. Always verify current requirements with Cigna and consult your healthcare team for medical decisions. For personalized assistance with prior authorizations and appeals, consider consulting with coverage advocacy services.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.